Skip to main content

Table 1 Characteristics of patients with IPMNs in the low-grade group and high-grade group

From: Radiomic nomogram based on MRI to predict grade of branching type intraductal papillary mucinous neoplasms of the pancreas: a multicenter study

Characteristics

Training set (n = 103)

External Validation set 1 (n = 48)

External Validation set 2 (n = 51)

Low grade (n = 77)

High grade (n = 26)

P-value

Low grade (n = 38)

High grade (n = 10)

P-value

Low grade (n = 37)

High grade (n = 14)

P-value

Gender

  

0.683

  

0.854

  

0.792

 Male

53

19

 

23

7

 

27

9

 

 Female

24

7

 

15

3

 

10

5

 

Age (year, range)

46 ~ 83

49 ~ 79

0.185

47–79

51–80

0.061

48–79

46–79

0.647

Symptom

  

0.122

  

0.336

  

0.107

 Yes

31

15

 

14

6

 

12

8

 

 No

46

11

 

24

4

 

25

6

 

Largest cyst size (cm)

  

0.042

  

0.044

  

0.020

 > 3

27

15

 

11

7

 

13

10

 

 ≤ 3

50

11

 

27

3

 

24

4

 

Size of MPD (cm)

  

0.005

  

0.047

  

0.002

 No dilatation

28

3

 

11

1

 

12

1

 

 ≤ 5

32

2

 

15

1

 

16

2

 

 5 ~ 10

12

13

 

10

6

 

7

5

 

 ≥ 10

5

8

 

2

2

 

2

6

 

Enhancing mural nodule

  

0.027

  

0.017

  

0.014

 Yes

18

12

 

9

7

 

10

9

 

 No

59

14

 

29

3

 

27

5

 

Thickened and enhancing cyst walls

  

0.116

  

0.278

  

0.247

 Yes

20

11

 

12

5

 

12

7

 

 No

57

15

 

26

5

 

25

7

 

Abrupt change in caliber of pancreatic duct with distal pancreatic atrophy

  

0.694

  

0.569

  

0.644

 Yes

15

6

 

6

3

 

9

5

 

 No

62

20

 

32

7

 

28

9

 

CA19–9, kU/L

  

<  0.001

  

0.001

  

<  0.001

 Normal

65

10

 

31

3

 

33

5

 

 Elevated

12

16

 

7

7

 

4

9

 

CEA, ng/mL

  

0.978

  

0.215

  

0.714

 Normal

62

21

 

32

6

 

30

10

 

 Elevated

15

5

 

6

4

 

7

4

 

Indication for surgery

  

0.034

  

0.040

  

0.013

 High risk factors

14

10

 

7

5

 

6

7

 

 No high risk factors

63

16

 

31

5

 

31

7

 
  1. MPD Main pancreatic duct, CA 19–9 Carbohydrate antigen, CEA Carcinoembryonic antigen